PMID- 24385120
OWN - NLM
STAT- MEDLINE
DCOM- 20140828
LR  - 20151119
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 13
IP  - 1
DP  - 2014 Jan
TI  - Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% 
      for the treatment of moderate to severe facial erythema of rosacea: results of a 
      1-year open-label study.
PG  - 56-61
AB  - Once-daily topical brimonidine tartrate (BT) gel 0.5% was shown to be efficacious 
      and safe for the treatment of erythema of rosacea in previous studies including a 
      4-week treatment phase. In the present 1-year study, we aimed to assess the 
      long-term safety and efficacy of the treatment. Subjects with moderate to severe 
      erythema of rosacea were instructed to apply topical BT gel 0.5% once daily for 
      12 months. Severity of erythema and adverse events (AEs) were evaluated. 
      Approximately 345 subject years of exposure to BT gel 0.5% was achieved in the 
      study. The incidence of AEs and AEs judged to be related to the study drug was 
      higher at the beginning and decreased over the course of the study. Similar 
      safety profiles were observed between the subjects who had received or not 
      received concomitant therapies for the inflammatory lesions of rosacea. Effect of 
      topical BT gel 0.5% on erythema severity was observed after the first application 
      and the durability of the effect was maintained until the end of the study at 
      month 12, with no tachyphylaxis observed. In conclusion, once-daily topical BT 
      gel 0.5% is safe and consistently effective for the long-term treatment of 
      moderate to severe erythema of rosacea, even in the presence of concomitant 
      therapies for the inflammatory lesions of rosacea.
FAU - Moore, Angela
AU  - Moore A
FAU - Kempers, Steven
AU  - Kempers S
FAU - Murakawa, George
AU  - Murakawa G
FAU - Weiss, Jonathan
AU  - Weiss J
FAU - Tauscher, Amanda
AU  - Tauscher A
FAU - Swinyer, Leonard
AU  - Swinyer L
FAU - Liu, Hong
AU  - Liu H
FAU - Leoni, Matthew
AU  - Leoni M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - 0 (Adrenergic alpha-Agonists)
RN  - 0 (Quinoxalines)
RN  - 4S9CL2DY2H (Brimonidine Tartrate)
SB  - IM
MH  - Administration, Cutaneous
MH  - Administration, Topical
MH  - Adrenergic alpha-Agonists/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brimonidine Tartrate
MH  - Erythema/drug therapy
MH  - Face/*pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Quinoxalines/administration & dosage/adverse effects/*therapeutic use
MH  - Rosacea/*drug therapy/pathology/psychology
MH  - Social Behavior
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2014/01/05 06:00
MHDA- 2014/08/29 06:00
CRDT- 2014/01/04 06:00
PHST- 2014/01/04 06:00 [entrez]
PHST- 2014/01/05 06:00 [pubmed]
PHST- 2014/08/29 06:00 [medline]
AID - S1545961614P0056X [pii]
PST - ppublish
SO  - J Drugs Dermatol. 2014 Jan;13(1):56-61.